ArticleCureus2022
West Nile Neuroinvasive Disease Treated With High-Dose Corticosteroids.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 6 citations in OpenAlex.
- West Nile Neuroinvasive Disease: Current Management, Emerging Therapies and Future Clinical Trial Priorities.Reviews in medical virology · 2026Review
- The Impact of Corticosteroid Therapy on Patients With West Nile Virus: A Retrospective Cohort Study.The Journal of infectious diseases · 2026Article
- Pharmaceutical Strategies for West Nile Virus in Europe, an Underrecognized Cause of Severe Disease and Mortality in Older Adults: From Supportive Care to Antiviral Development.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Severe Usutu Virus Encephalitis Treated With Corticosteroids: A Case Report.Case reports in infectious diseases · 2026Article
- A central role for CCR2 in monocyte recruitment and blood-brain barrier disruption during Usutu virus encephalitis.Journal of neuroinflammation · 2025Article
- Clinical Characteristics and Mechanism Discussion of Peripheral Nerve Injury in 2 Cases of Severe Viral Meningoencephalitis.Journal of inflammation research · 2025Article
- West Nile virus seropositivity in Alanya, a coastal city in the Mediterranean region of Turkey.Annals of Saudi medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
West Nile neuroinvasive disease, which includes encephalitis, meningitis, or acute flaccid paralysis, is one of the two most common manifestations of West Nile virus (WNV). According to many national agencies, since 1999, WNV has been one of the most common causes of epidemic viral encephalitis in the United States, especially in the state of California, and it will likely remain an important cause of neurological disease for years to come. To date, the mainstay of treatment for West Nile neuroinvasive disease has been supportive care with no data to support the routine use of any agents. Here, we present a unique case of West Nile encephalitis in a 61-year-old male who was successfully treated with a five-day course of high-dose corticosteroids. Although this rapid improvement could be a mere coincidence, it facilitates the need for further trials to determine if high-dose corticosteroids and other drugs may benefit patients in the treatment of West Nile neuroinvasive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.